BRAXF News and Press, Braxia Scientific Corp From 08/30/21

Braxia Scientific Reports First Quarter 2022 Financial Results; Company Achieves 80% Revenue Growth from Expanding Clinic Patient Base PR Newswire Revenue from four Canadian clinics increased 80.3% to $407,075 year-over-year Exceeding monthly IV Ketamine ...

Delta, Kelowna, BC - August 27, 2021 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today's podcast edition of cannabis news and stocks to watch plus insi...

Braxia Scientific to Commence Landmark Clinical Trial to Conduct Canada's First Multiple-Dose Psilocybin Clinical Trial for Treatment Resistant Depression PR Newswire First multiple-dose psilocybin clinical trial will be conducted at Braxia Health's Canadian Rapid Trea...

Braxia Scientific Announces Participation at H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 Canada NewsWire TORONTO , Aug. 17, 2021 /CNW/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (...

Braxia Scientific Announces Participation at Canaccord Genuity 2021 Annual Growth Conference August 10-12 Canada NewsWire TORONTO , Aug. 6, 2021 /CNW Telbec/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a m...

Braxia Scientific (OTCPK:BRAXF): Q4 Net and comprehensive losses of C$2.6M Revenue of C$0.35M Press Release For further details see: Braxia Scientific reports Q4 results

Braxia Scientific Provides Corporate Update and Reports Fiscal Fourth Quarter and Full-Year 2021 Financial Results Canada NewsWire TORONTO , July 30, 2021 /CNW/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), toda...

Braxia Scientific CEO, Chief Medical Officer Awarded $918,000 by Canadian Government to Study Benefits of Integrating Ketamine with Cognitive Behavioural Therapy to Reduce Suicidality Canada NewsWire Innovative Ketamine clinical trial ranked in the 94th percentile by t...

Braxia Scientific Secures Approval for Direct Billing Insurance on Ketamine Treatments for Veterans Affairs Canada Clients Canada NewsWire TORONTO , July 20, 2021 /CNW Telbec/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: ...

Braxia Scientific to Discuss Psychiatric Treatment Discovery and Development with Oxford University Researchers at AIMday Experimental Medicine in Psychiatry on July 7, 2021 Canada NewsWire TORONTO , July 7, 2021 /CNW/ - Braxia Scientific Corp. ("Braxia", or...